Debu Tripathy, MD is Professor of Clinical Medicine, Co-Leader of the Women’s Cancer Program and holds the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California and USC/Norris Comprehensive Cancer Center. He received a degree in Chemical Engineering from the Massachusetts Institute of Technology and then competed medical school and an internal medicine residency at Duke University followed by a Hematology/Oncology fellowship at the University of California at San Francisco. His clinical research focuses on the evaluation and development of novel therapeutics in breast cancer, specifically, growth factor receptor pathway targeting as well as biomarkers that predict sensitivity and resistance. Elucidation of specific mechanisms of resistance and synthetic lethal combinatorial strategies from the laboratory are being applied for early phase therapeutic applications. Similarly, human tissue studies from patients receiving conventional and targeted therapies are being analyzed toward the discovery of novel targets and predictive biomarkers. Dr. Tripathy is also part of a multi-disciplinary team of breast cancer specialists dedicated to patient-centered state-of-the-art and personalized approaches to care, with an emphasis on clinical trials that interface with the basic scientific strengths at USC and external collaborators. Dr. Tripathy has published numerous original laboratory and clinical research articles in the area of breast cancer and serves on several editorial boards, study sections and societies as well as Editor-in-Chief of CURE Magazine. He has previously served as the President of the American Society of Breast Disease and the Society of Integrative Oncology.